On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
The approval was much anticipated by patients and clinicians alike, ever since the dramatic results of the RASolute-302 trial, a randomized, open-label, multicenter clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma, were published.
In the trial, daraxonrasib nearly doubled median overall survival to 13.2 months compared to 6.7 months for standard chemotherapy, a historic increase in a disease whose overall survival has stagnated for decades.
In this week’s episode of In the Headlines, Jacquelyn Cobb, associate editor with The Cancer Letter, speaks with Brian M. Wolpin, principal investigator for the RASolute-302 trial about his involvement in the clinical testing of daraxonrasib, what the scientific milestone means for his patients, and what to look out for next in the pancreatic cancer research space.
Wolpin is the director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute.
“This really is the future of the field, I think, which is: KRAS is sort of the director of the orchestra in pancreatic cancer,” Wolpin said. “Once you inhibit that, you can then go after so many other aspects of pancreatic cancer biology and use it, use these new medicines in a way that if they were given by themselves, they wouldn't work as well.”
Stories mentioned in this podcast include:
A transcript of this podcast is available: https://cancerletter.com/podcastc/20260902-daraxonrasib/
